1. Market Research
  2. > Bionovo, Inc. – Product Pipeline Review – 2013

Bionovo, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 50 pages

Bionovo, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Bionovo, Inc. - Product Pipeline Review - 2013” provides data on the Bionovo, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Bionovo, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Bionovo, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Bionovo, Inc. - Brief Bionovo, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bionovo, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bionovo, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bionovo, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Bionovo, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bionovo, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bionovo, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bionovo, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bionovo, Inc. and identify potential opportunities in those areas.

Table Of Contents

Bionovo, Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Bionovo, Inc. Snapshot 5
Bionovo, Inc. Overview 5
Key Information 5
Key Facts 5
Bionovo, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Bionovo, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Bionovo, Inc. - Pipeline Products Glance 10
Bionovo, Inc. - Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Bionovo, Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Bionovo, Inc. - Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Bionovo, Inc. - Drug Profiles 13
BN-107 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
BN-108 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
BZL-101 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
MF-101 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Bionovo, Inc. - Pipeline Products by Route of Administration 19
Bionovo, Inc. - Pipeline Products By Mechanism of Action 20
Bionovo, Inc. - Recent Pipeline Updates 21
Bionovo, Inc. - Locations And Subsidiaries 24
Head Office 24
Bionovo, Inc., Recent Developments 25
Bionovo, Inc.- Press Release 25
Dec 13, 2010: Bionovo Releases FDA-Approved Clinical Development Plan For Menerba 25
Nov 10, 2010: Bionovo Receives FDA Approval For Clinical Development Plan Of Menerba 25
Sep 23, 2010: Bionovo Receives FDA Approval For Menerba Manufacturing Plan 26
Aug 30, 2010: Bionovo Receives Positive Guidance From FDA On Menerba 27
Aug 02, 2010: Bionovo Announces Publication Describing Menerba's Effect On Neural Pathways Related To Temperature Regulation 28
Jul 29, 2010: Bionovo To Advance Menerba to Phase III Clinical Testing In Europe 28
Apr 20, 2010: Bionovo Receives Patent For Bezielle For Treatment Of Metastatic Breast Cancer 29
Jan 14, 2010: Bionovo Announces Results From Phase 1B Clinical Trial Of Bezielle (BZL101) For Metastatic Breast Cancer 29
Financial Deals Landscape 31
Bionovo, Inc., Deals Summary 31
Bionovo, Inc., Pharmaceuticals and Healthcare, Deal Details 32
Equity Offering 32
BioNovo Announces Private Placement Of Common Stock And Warrants For US$0.43 Million 32
BioNovo Completes Private Placement Of Preferred Stock For US$0.1 Million 33
Bionovo Files Registration Statement For Public Offering Of Preferred Stock And Warrants For US$25 Million 35
Bionovo Completes An Underwritten Public Offering For US$30 Million 36
Bionovo Completes Registered Direct Offering Of US$3 Million 38
Bionovo Announces Private Placement Of US$15 Million 40
Bionovo Files Registration Statement For Public Offering Of US$100 Million 42
Bionovo Completes Public Offering Of US$19 Million 43
Bionovo Completes Public Offering Of US$25.53 Million 45
Bionovo Completes Private Placement Of US$15.78 Million 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables

Bionovo, Inc., Key Information 5
Bionovo, Inc., Key Facts 5
Bionovo, Inc. - Pipeline by Indication, 2013 7
Bionovo, Inc. - Pipeline by Stage of Development, 2013 8
Bionovo, Inc. - Monotherapy Products in Pipeline, 2013 9
Bionovo, Inc. - Phase III, 2013 10
Bionovo, Inc. - Phase II, 2013 11
Bionovo, Inc. - Pre-Clinical, 2013 12
Bionovo, Inc. - Pipeline By Route of Administration, 2013 19
Bionovo, Inc. - Pipeline Products By Mechanism of Action, 2013 20
Bionovo, Inc. - Recent Pipeline Updates, 2013 21
Bionovo, Inc., Deals Summary 31
BioNovo Announces Private Placement Of Common Stock And Warrants For US$0.43 Million 32
BioNovo Completes Private Placement Of Preferred Stock For US$0.1 Million 33
Bionovo Files Registration Statement For Public Offering Of Preferred Stock And Warrants For US$25 Million 35
Bionovo Completes An Underwritten Public Offering For US$30 Million 36
Bionovo Completes Registered Direct Offering Of US$3 Million 38
Bionovo Announces Private Placement Of US$15 Million 40
Bionovo Files Registration Statement For Public Offering Of US$100 Million 42
Bionovo Completes Public Offering Of US$19 Million 43
Bionovo Completes Public Offering Of US$25.53 Million 45
Bionovo Completes Private Placement Of US$15.78 Million 47

List of Figures

Bionovo, Inc. - Pipeline by Indication, 2013 7
Bionovo, Inc. - Pipeline by Stage of Development, 2013 8
Bionovo, Inc. - Monotherapy Products in Pipeline, 2013 9
Bionovo, Inc. - Pipeline Products By Mechanism of Action, 2013 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.